$SLDB News

Solid Biosciences: The Bull Case Is No Longer Just Duchenne

Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

HC Wainwright & Co. Maintains Buy on Solid Biosciences, Raises Price Target to $25

Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Participate at Upcoming Investor Conferences

Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?

Wedbush Reiterates Outperform on Solid Biosciences, Maintains $16 Price Target

Wedbush Maintains Outperform on Solid Biosciences, Lowers Price Target to $16

Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences Q1 EPS $(0.52) Misses $(0.44) Estimate

Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy

Solid Biosciences Doses First Participant In Phase 3 IMPACT DUCHENNE Clinical Trial For SGT-003 In Duchenne Muscular Dystrophy

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences Says European Commission Grants Orphan Drug Designation To SGT-003 For Treatment Of Duchenne Muscular Dystrophy

Solid Biosciences to Participate at Upcoming Investor Conferences

JP Morgan Maintains Overweight on Solid Biosciences, Raises Price Target to $12